Vanguard Group Inc. Has $118.63 Million Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Vanguard Group Inc. boosted its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 37.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 15,506,834 shares of the company's stock after buying an additional 4,247,002 shares during the period. Vanguard Group Inc. owned approximately 7.16% of Recursion Pharmaceuticals worth $118,627,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. increased its stake in Recursion Pharmaceuticals by 116.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,237 shares of the company's stock valued at $40,000 after buying an additional 2,817 shares during the last quarter. Amundi raised its holdings in Recursion Pharmaceuticals by 69.6% during the fourth quarter. Amundi now owns 7,189 shares of the company's stock worth $57,000 after acquiring an additional 2,949 shares in the last quarter. Baldwin Brothers LLC MA raised its holdings in Recursion Pharmaceuticals by 33.3% during the third quarter. Baldwin Brothers LLC MA now owns 7,336 shares of the company's stock worth $56,000 after acquiring an additional 1,834 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in Recursion Pharmaceuticals by 25.4% during the third quarter. Allspring Global Investments Holdings LLC now owns 10,123 shares of the company's stock valued at $77,000 after purchasing an additional 2,050 shares during the last quarter. Finally, Private Advisor Group LLC bought a new position in Recursion Pharmaceuticals in the third quarter valued at approximately $79,000. Institutional investors own 89.06% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on RXRX. TD Cowen started coverage on shares of Recursion Pharmaceuticals in a report on Friday, January 26th. They set a "market perform" rating on the stock. Needham & Company LLC boosted their price objective on shares of Recursion Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a research note on Wednesday, February 28th. Finally, KeyCorp raised their target price on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an "overweight" rating in a research note on Monday, March 4th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $12.75.

Insider Activity

In related news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $8.82, for a total value of $100,962.54. Following the transaction, the director now directly owns 7,241,308 shares of the company's stock, valued at $63,868,336.56. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the business's stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $8.82, for a total value of $100,962.54. Following the transaction, the director now directly owns 7,241,308 shares of the company's stock, valued at $63,868,336.56. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Christopher Gibson sold 48,272 shares of the business's stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $9.22, for a total transaction of $445,067.84. Following the transaction, the chief executive officer now owns 774,703 shares in the company, valued at approximately $7,142,761.66. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 373,701 shares of company stock valued at $4,069,001. Insiders own 19.96% of the company's stock.

Recursion Pharmaceuticals Price Performance

RXRX traded down $0.20 on Thursday, hitting $8.73. 4,720,211 shares of the stock were exchanged, compared to its average volume of 7,109,758. The business has a 50-day moving average of $11.05 and a two-hundred day moving average of $9.06. The firm has a market capitalization of $2.05 billion, a price-to-earnings ratio of -5.63 and a beta of 0.76. Recursion Pharmaceuticals, Inc. has a 12 month low of $4.54 and a 12 month high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.46) by $0.06. The business had revenue of $10.89 million during the quarter, compared to analysts' expectations of $12.37 million. Recursion Pharmaceuticals had a negative net margin of 735.99% and a negative return on equity of 72.88%. Equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.